fatty acid metabolic

Triheptanoin (IND 106011) 是合成的中链甘油三酯 (MCT)，由甘油主链上的三个奇数链 7-碳(庚酸)脂肪酸组成，可以用于研究遗传代谢紊乱。

Orlistat (Tetrahydrolipstatin) 是一种脂肪酶 (lipase) 抑制剂，也是一种脂肪酸合成酶 (FASN) 抑制剂。Orlistat 具有促减肥的作用。

L-Carnitine (L(-)-Carnitine) 是一种人内源性分子，在人体内以蛋氨酸和赖氨酸为底物进行生物合成，并参与脂肪酸代谢。L-Carnitine 将长链脂肪酰辅酶A 转运到线粒体。L-Carnitine 能够改善许多先天性代谢错误的代谢失衡。

Lycorine (Narcissine) 是从金眼科植物科中提取的一种天然生物碱。它是一种具有口服活性的SCAP 抑制剂，Kd 值 15.24 nM。它也是黑色素瘤血管生成抑制剂，有用于前列腺癌和代谢疾病的研究潜力。

Suberic acid (1,8-Octanedioic acid) 被发现和肉毒碱-甲酰基-丙氨酸转位酶缺乏(丙二醇-羧基酶缺乏症)有关。

D-Pantothenic acid (vitamin B5) 是必需的微量营养素，是辅酶 A 的前体，在很多生物过程中发挥关键作用，如调节碳水化合物，脂质，蛋白和核酸代谢。

10,12-Tricosadiynoic acid 是一种口服有效的酰基辅酶 A 氧化酶-1 (ACOX1) 抑制剂，具有高特异性，选择性，高亲和力的特点。10,12-Tricosadiynoic acid 可改善线粒体脂质和 ROS 代谢，在高脂饮食或肥胖引起的代谢性疾病中有研究的价值。

3-Hydroxydodecanoic acid is a medium-chain fatty acid commonly linked to fatty acid metabolic disorders.

(R)-Aminocarnitine (Emeriamine) TFA 是用于代谢性疾病研究的脂肪酸氧化抑制剂，它能有效减少高血糖和酮症的发生。

Trimetazidine, an anti-ischemic (anti-anginal) metabolic agent, could improve myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity and results in a reduction in fatty acid oxidation and a stimulation of glucose

Palmitic acid-13C (C1, C2, C3, and C4 labeled) is intended for use as an internal standard for the quantification of palmitic acid by GC- or LC-MS. Palmitic acid is a common 16-carbon saturated fat that represents 10-20% of human dietary fat intake and comprises approximately 25 and 65% of human total plasma lipids and saturated fatty acids, respectively.1,2Acylation of palmitic acid to proteins facilitates anchoring of membrane-bound proteins to the lipid bilayer and trafficking of intracellular proteins, promotes protein-vesicle interactions, and regulates various G protein-coupled receptor functions.1Red blood cell palmitic acid levels are increased in patients with metabolic syndrome compared to patients without metabolic syndrome and are also increased in the plasma of patients with type 2 diabetes compared to individuals without diabetes.3,4 1.Fatima, S., Hu, X., Gong, R.-H., et al.Palmitic acid is an intracellular signaling molecule involved in disease developmentCell. Mol. Life Sci.76(13)2547-2557(2019) 2.Santos, M.J., López-Jurado, M., Llopis, J., et al.Influence of dietary supplementation with fish oil on plasma fatty acid composition in coronary heart disease patientsAnn. Nutr. Metab.39(1)52-62(1995) 3.Yi, L.-Z., He, J., Liang, Y.-Z., et al.Plasma fatty acid metabolic profiling and biomarkers of type 2 diabetes mellitus based on GC/MS and PLS-LDAFEBS Lett.580(30)6837-6845(2006) 4.Kabagambe, E.K., Tsai, M.Y., Hopkins, P.N., et al.Erythrocyte fatty acid composition and the metabolic syndrome: A National Heart, Lung, and Blood Institute GOLDN studyClin. Chem.54(1)154-162(2008)

ZLY032 is a dual agonist of free fatty acid receptor 1 (FFAR1 GPR40; EC50= 68 nM in a FLIPR assay) and peroxisome proliferator-activated receptor δ (PPARδ; EC50= 102 nM in a reporter assay).1It is selective for FFAR1 and PPARδ over PPARα and PPARγ (EC50s = >10 μM for both). ZLY032 (40 mg kg, twice per day) reduces blood glucose levels in an oral glucose tolerance test and decreases plasma total cholesterol and triglyceride levels in theob obmouse model of metabolic disease.2It reduces hepatic steatosis and plasma alanine transaminase (ALT) and aspartate aminotransferase (AST) levels in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a methionine and choline-deficient diet at the same dose. 1.Li, Z., Chen, Y., Zhou, Z., et al.Discovery of first-in-class thiazole-based dual FFA1 PPARδ agonists as potential anti-diabetic agentsEur. J. Med. Chem.164352-365(2019) 2.Li, Z., Zhou, Z., Hu, L., et al.ZLY032, the first-in-class dual FFA1 PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosisPharmacol Res.159105035(2020)

10-PAHSA is a newly identified endogenous lipid that belongs to a collection of branched fatty acid esters of hydroxy fatty acids (FAHFAs). It is a FAHFA in which palmitic acid is esterified to 10-hydroxy stearic acid. Among the FAHFA family members, PAHSAs are the most abundant in the adipose tissue of glucose tolerant AG4OX mice, which overexpress the Glut4 glucose transporter specifically in adipose tissue. As other FAHFAs improve glucose tolerance, stimulate insulin secretion, and have anti-inflammatory effects, 10-PAHSA may be a bioactive lipid with roles in metabolic syndrome and inflammation.

Methylmalonyl coenzyme A (methylmalonyl-CoA) is an intermediate in multiple metabolic pathways in bacteria and eukaryotes.1,2,3It is an intermediate in carbon assimilation in certain bacteria and carbon fixation in plants.1,2Methylmalonyl-CoA is converted to succinyl-CoA by methylmalonyl-CoA mutase with vitamin B12as a coenzyme.3A deficiency in vitamin B12leads to a build-up of methylmalonyl-CoA.4 1.Anthony, C.How half a century of research was required to understand bacterial growth on C1 and C2 compounds; the story of the serine cycle and the ethylmalonyl-CoA pathwaySci. Prog.94(Pt 2)109-137(2011) 2.Tabita, F.R.The hydroxypropionate pathway of CO2 fixation: Fait accompliProc. Natl. Acad. Sci. U.S.A.106(50)21015-21016(2009) 3.Medicine, I.o.Vitamin B12Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline306-356(1998) 4.Cardinale, G.J., Carty, T.J., and Abeles, R.H.Effect of methylmalonyl coenzyme A, a metabolite which accumulates in vitamin B12 deficiency, on fatty acid synthesisJ. Biol. Chem.245(15)3771-3775(1970)

Octanoyl coenzyme A (octanoyl-CoA) is a medium-chain acyl CoA and a metabolic intermediate in mitochondrial fatty acid β-oxidation. Levels of octanoyl-CoA are increased in the liver of patients with Reye's syndrome and β-oxidation of octanoyl-CoA by medium-chain acyl CoA dehydrogenase (MCADH) is decreased in patients with MCADH deficiency (MCD). Octanoyl-CoA inhibits citrate synthase and glutamate dehydrogenase.

Carnitine facilitates the transport of fatty acids into the mitochondria to be used in fatty acid metabolism. It does so by accepting acyl groups from fatty acids complexed with coenzyme A, which yields esterified carnitine or acylcarnitines that enable the transport of fatty acyl groups into the inner mitochondrial matrix. β-Oxidation of fatty acids in mitochondria is inhibited by uncoupling conditions, thus changes in circulating levels of various acylcarnitines have been used to identify alterations in metabolic state.[1] [2] Arachidonoyl-L-carnitine formed from carnitine conjugated to arachidonic acid .

Phospholipase A2 (PLA2) catalyzes the hydrolysis of phospholipids at the sn-2 position leading to the production of lysophospholipids and free fatty acids. Calcium-dependent cytosolic PLA2 (cPLA2α) is a 85 kDa enzyme that plays a key role in the arachidonic cascade and the inflammatory response associated with this metabolic pathway. CAY10502 is a potent inhibitor of calcium-dependent cytosolic PLA2α (cPLA2α) with an IC50 value of 4.3 nM for the purified enzyme from human platelets. It inhibits arachidonic acid mobilization from A23187-stimulated or TPA-stimulated human platelets with IC50 values of 570 and 0.9 nM, respectively.

The endocannabinoids, 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide (AEA), are biologically active lipids that regulate diverse neurological and metabolic functions by activating the cannabinoid receptors, central cannabinoid (CB1) and peripheral cannabinoid (CB2). Monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH) hydrolyze 2-AG and AEA, respectively, thus terminating their biological function. IDFP is an organophosphorus compound that dually inhibits MAGL and FAAH with IC50 values of 0.8 and 3 nM, respectively. At 10 mg/kg, IDFP elevates brain levels of 2-AG and AEA more than 10-fold, and decreases levels of arachidonic acid by a similar magnitude.

Galactosylcerebrosides are glycosphingolipids that contain a galactose attached to a ceramide acylated with a hydroxy or non-hydroxy fatty acid. They are metabolic precursors to sulfatides , found primarily in nerve tissues, and are the main glycosphingolipids in the central nervous system. Galactosylcerebrosides are involved in a multitude of cellular processes including cell agglutination, cellular signaling in glycosynapses, cellular development, and activation of T cells. They accumulate in globoid cells in the brain of patients with Krabbe disease, a disorder characterized by a deficiency in galactosylcerebrosidase activity. This product is a mixture of isolated bovine hydroxy galactosylcerebrosides.

Galactosylcerebrosides are glycosphingolipids that contain a galactose attached to a ceramide acylated with a hydroxy or non-hydroxy fatty acid. They are metabolic precursors to sulfatides , found primarily in nerve tissues, and are the main glycosphingolipids in the central nervous system. Galactosylcerebrosides are involved in a multitude of cellular processes including cell agglutination, cellular signaling in glycosynapses, cellular development, and activation of T cells. They accumulate in globoid cells in the brain of patients with Krabbe disease, a disorder characterized by a deficiency in galactosylcerebrosidase activity. This product is a mixture of isolated bovine non-hydroxy galactosylcerebrosides.

Certain chronic neurologic disorders, such as Parkinson's disease, are caused by an insufficiency of the neurotransmitter dopamine secondary to the degeneration of substantia nigra dopaminergic neurons. N-(α-Linolenoyl) tyrosine (NALT) is a simple α-amide conjugate between the ω-3 essential fatty acid α-linolenate and the amino acid tyrosine. α-Linolenate is an important precursor to docosahexaenoic acid (DHA), a prominent brain polyunsaturated fatty acid, while tyrosine is the metabolic precursor for neuronal dopamine synthesis. NALT was prepared as a method for enhancing central nervous system (CNS) dopamine content by facilitated transport of the tyrosine precursor across the blood-brain barrier. In experimental rat models of dopamine insufficiency, NALT increased CNS dopamine levels and exhibited an activity profile consistent with an anti-Parkinson's therapeutic agent.

FATP1-IN-2 是一种脂肪酸转运蛋白1 (FATP1) 抑制剂，具有口服活性，可用于研究肥胖和代谢疾病。

12(S)-HHT(12(S)-HHTrE)是通过环氧化酶（COX）的花生四烯酸代谢途径生成的脂肪酸，是BLT2的内源性配体和激动剂，12(S)-HHT BLT2轴在维持上皮组织稳态方面和炎症反应中起作用。12-HHT通过上调MKP-1抑制p38 MAPK NF-κB通路，导致UVB照射的HaCaT细胞的IL-6合成减少。

N-(3-Phenylpropionyl)glycine (Phenylpropionylglycine) 是一种酰基甘氨酸。酰基甘氨酸通常是脂肪酸的次要代谢物。